U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H32N8O2
Molecular Weight 500.5954
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ADAVOSERTIB

SMILES

CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=NC(=CC=C5)C(C)(C)O)C=C2

InChI

InChIKey=BKWJAKQVGHWELA-UHFFFAOYSA-N
InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)

HIDE SMILES / InChI
Molecular Formula C27H32N8O2
Molecular Weight 500.5954
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=594147 | http://adisinsight.springer.com/drugs/800028808 | https://ncats.nih.gov/files/AZD1775.pdf

AZD1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Current ongoing trials of AZD1775 include monotherapy and combination therapy with certain DNA damaging agents in solid tumors, ovarian tumors, gynaecological cancer, non-small cell lung cancer. AZD1775 is genotoxic, which is considered to be a result of its mechanism of action. Common serious adverse events (with chemotherapy) include: febrile neutropenia, neutropenia, thrombocytopenia.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 5.2 nM [IC50]
Inhibitor
8297
 14.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
Other AEs: vomiting, fatigue...
Other AEs:
vomiting (grade 2, 2 patients)
fatigue (grade 2, 1 pt)
anemia (grade 3, 1 pt)
hyponatremia (grade 3, 1 pt)
thrombocytopenia (grade 3, 2 patients)
nausea (grade 3, 2 patients)
Leukopenia (grade 4, 1 pt)
neutropenia (grade 4, 5 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
400 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: solid tumour
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
DLT: neutropenia, Pancytopenia...
Dose limiting toxicities:
neutropenia (grade 4, 1 pt)
Pancytopenia (grade 4, 1 pt)
Fatigue (grade 3, 1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Other AEs: Neutropenia, Lymphopenia...
Other AEs:
Neutropenia (grade 3, 2 patients)
Lymphopenia (grade 3, 1 pt)
Thrombocytopenia (grade 3, 1 pt)
anemia (grade 3, 1 pt)
Leucopenia (grade 3, 1 pt)
Nausea (grade 3, 1 pt)
Diarrhea (grade 3, 1 pt)
Hypophosphatemia (grade 3, 1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
300 mg 2 times / day multiple, oral (unknown)
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 3
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
DLT: Myelosuppression, Supraventricular tachyarrhythmia...
Dose limiting toxicities:
Myelosuppression (grade 4, 1 pt)
Supraventricular tachyarrhythmia (1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
AEs

AEs

AESignificanceDosePopulation
fatigue grade 2, 1 pt
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
vomiting grade 2, 2 patients
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
anemia grade 3, 1 pt
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
hyponatremia grade 3, 1 pt
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
nausea grade 3, 2 patients
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
thrombocytopenia grade 3, 2 patients
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
Leukopenia grade 4, 1 pt
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
neutropenia grade 4, 5 patients
300 mg 1 times / day multiple, oral (starting)
MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: solid tumor
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
Fatigue grade 3, 1 pt
DLT
400 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: solid tumour
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
Pancytopenia grade 4, 1 pt
DLT
400 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: solid tumour
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
neutropenia grade 4, 1 pt
DLT
400 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: solid tumour
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/33863809
Diarrhea grade 3, 1 pt
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Hypophosphatemia grade 3, 1 pt
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Leucopenia grade 3, 1 pt
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Lymphopenia grade 3, 1 pt
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Nausea grade 3, 1 pt
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Thrombocytopenia grade 3, 1 pt
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
anemia grade 3, 1 pt
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Neutropenia grade 3, 2 patients
225 mg 2 times / day multiple, oral (unknown)
MTD
Dose: 225 mg, 2 times / day
Route: oral
Route: multiple
Dose: 225 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 19
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Supraventricular tachyarrhythmia 1 pt
DLT, Disc. AE
300 mg 2 times / day multiple, oral (unknown)
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 3
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Myelosuppression grade 4, 1 pt
DLT, Disc. AE
300 mg 2 times / day multiple, oral (unknown)
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
unhealthy
n = 3
Health Status: unhealthy
Condition: solid tumors
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/25964244
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1461
OATP1A2
62

OATP2B1
104

OAT3
339

P-gp
1537

BCRP
561
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1819
 inconclusive [IC50 18.9991 uM]
CYP2D6
1891
 no
CYP3A4
1925
 no
P-gp
1650
 yes [IC50 3.7221 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OAT3
339
 no
OATP2B1
104
 no
BCRP
561
 yes
OATP1A2
62
 yes
P-gp
1537
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY116012
https://www.001chemical.com/chem/search?q=DY116012
1PlusChem LLC
1P003AL1
https://www.1pchem.com/search?query=1P003AL1
A2B Chem
AB52885
http://a2bchem.com/prod/AB52885
AChemBlock
M15123
http://www.achemblock.com/catalogsearch/result/?q=M15123
AK Scientific
SYN5698
https://aksci.com/item_detail.php?cat=SYN5698
AK Scientific
X7493
https://aksci.com/item_detail.php?cat=X7493
AOBIOUS INC
AOB87173
http://aobious.com/aobious/search?search_query=AOB87173
Ambeed
A399066
http://www.ambeed.com/search/Search.html?keyword=A399066
Angene
AGN-PC-0WH8XO
http://www.angenechemical.com/productshow/AGN-PC-0WH8XO.html
ApexBio Technology
A5755
https://www.apexbt.com/catalogsearch/result/?q=A5755
AstaTech
27926
http://astatechinc.com/CPSResult.php?CRNO=27926
Axon MedChem
1494
https://www.axonmedchem.com/product/1494
Cayman Chemical
21266
http://www.caymanchem.com/app/template/Product.vm/catalog/21266
Chem Scene
CS-0105
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0105
ChemShuttle
101254
https://www.chemshuttle.com/catalogsearch/result/?q=101254
Combi-Blocks
QJ-1903
http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-1903
Excenen
EX-A331
http://www.excenen.com/searchresultlist.php?id=EX-A331
Hairui
HR106075
http://www.hairuichem.com/en/product/search.do?q=HR106075
KeyOrganics
AS-17001
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-17001
Lab Seeker
SC-94519
http://www.labseeker.com/search.php?keywords=SC-94519&category=0
LabSeeker
SC-94519
http://www.labseeker.com/search.php?keywords=SC-94519&category=0
Matrix Scientific
120722
http://www.matrixscientific.com/120722.html
MedChem Express
HY-10993
https://www.medchemexpress.com/search.html?q=HY-10993&ft=&fa=&fp=
MolPort
MolPort-016-633-227
https://www.molport.com/shop/molecule-link/MolPort-016-633-227
Molcore
MC116012
http://www.molcore.com/CatMC116012.html
Molnova
M16820
https://www.molnova.com/en/serch-list.html?keywords=M16820
MuseChem
I005658
https://www.musechem.com/product/I005658.html
PI Chemicals
PI-38309
http://www.pipharm.com/catalog_products/PI-38309.html
Ryan Scientific
Mirabegron
https://ryansci.com/products?q=Mirabegron&list_q=&search_type=exact
ShangHai Biochempartner
BCP000191
http://www.biochempartner.com/search_BCP000191
ShangHai Biochempartner
BCP01928
http://www.biochempartner.com/search_BCP01928
TargetMol
T2077
https://www.targetmol.com/search?keyword=T2077
eMolecules
36000452
https://orderbb.emolecules.com/search/#?query=36000452
eNovation Chemicals
D572857
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D572857&searchbtn.x=0&searchbtn.y=0
mcule
MCULE-8668868093
https://mcule.com/MCULE-8668868093/
PubMed

PubMed

TitleDatePubMed
Patents

Patents

20070254892
2
20100063024
2
20100124544
2
20110189130
2

Sample Use Guides

In Vivo Use Guide
The starting dose was 225 mg twice per day over 2.5 days for 1 week of a 21-day cycle. With subsequent dose escalations, at 225 mg or 300 mg twice per day for 2.5 days per week for 2 consecutive weeks of a 21-day cycle.
Route of Administration: Oral
In Vitro Use Guide
AZD1775 inhibits Wee1 activity and induces DNA damage as well as G2 checkpoint escape in cell-based assays with an EC50 of about 80 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:31:35 UTC 2023
Edited
by admin
on Fri Dec 15 15:31:35 UTC 2023
Record UNII
K2T6HJX3I3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ADAVOSERTIB
USAN   INN  
Official Name English
1,2-DIHYDRO-1-(6-(1-HYDROXY-1-METHYLETHYL)-2-PYRIDINYL)-6-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-2-(2-PROPEN-1-YL)-3H-PYRAZOLO(3,4-D)PYRIMIDIN-3-ONE
Systematic Name English
1-[6-(2-Hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-(prop-2-en-1-yl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
Systematic Name English
ADAVOSERTIB [USAN]
Common Name English
3H-PYRAZOLO(3,4-D)PYRIMIDIN-3-ONE, 1,2-DIHYDRO-1-(6-(1-HYDROXY-1-METHYLETHYL)-2-PYRIDINYL)-6-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-2-(2-PROPEN-1-YL)-
Systematic Name English
MK-1775
Code English
MK1775
Code English
AZD-1775
Code English
adavosertib [INN]
Common Name English
Adavosertib [WHO-DD]
Common Name English
AZD1775
Code English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
Code System Code Type Description
USAN
FG-33
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
PUBCHEM
24856436
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
DRUG BANK
DB11740
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
CAS
955365-80-7
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
EU-Orphan Drug
EU/3/12/989(POSITIVE)
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY treatment of ovarian cancer
NCI_THESAURUS
C91725
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
SMS_ID
100000177968
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
ChEMBL
CHEMBL1976040
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
WIKIPEDIA
Adavosertib
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
FDA UNII
K2T6HJX3I3
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
INN
10667
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
EPA CompTox
DTXSID30241868
Created by admin on Fri Dec 15 15:31:35 UTC 2023 , Edited by admin on Fri Dec 15 15:31:35 UTC 2023
PRIMARY
Related Record Type Details
Structure of ADAVOSERTIB HEMIHYDRATE
SOLVATE->ANHYDROUS
Structure of ADAVOSERTIB HEMIHYDRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of ADAVOSERTIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966